 | |
| Clinical data | |
|---|---|
| Trade names | Colpotrofin, Colpotrophine, Delipoderm |
| Other names | Estradiol 3-propyl 17β-methyl diether; 17β-Methoxy-3-propoxyestra-1,3,5(10)-triene |
| Routes of administration | Topical |
| Drug class | Estrogen;Estrogen ester |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.049.401 |
| Chemical and physical data | |
| Formula | C22H32O2 |
| Molar mass | 328.496 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Promestriene (INNTooltip International Nonproprietary Name) (brand namesColpotrofin,Colpotrophine,Delipoderm), also known asestradiol 3-propyl 17β-methyl diether, is asyntheticestrogen which is usedtopically in a 1%cream formulation for the treatment ofvaginal atrophy in women.[1][2][3][4][5] It is the 3-propyl and 17β-methyldiether ofestradiol and does not appear to convert into estradiol in the body.[1][6] Promestriene is minimallyabsorbed and appears to have negligible systemic estrogenic effect.[1] The drug has been described as atropic agent andantiseborrheic.[2] It has not been found to be effective in the treatment ofpattern hair loss or other conditions ofcutaneousandrogenization.[7][8] Promestriene was first introduced inFrance in 1974 and has been marketed in 34 countries worldwide.[1] It has been used in millions of women.[1]
 | Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it. |
